Literature DB >> 19524545

Hypoxia and the metabolic phenotype of prostate cancer cells.

L H Higgins1, H G Withers, A Garbens, H D Love, L Magnoni, S W Hayward, C D Moyes.   

Abstract

Many cancer cells have an unusual ability to grow in hypoxia, but the origins of this metabolic phenotype remain unclear. We compared the metabolic phenotypes of three common prostate cancer cell models (LNCaP, DU145, PC3), assessing energy metabolism, metabolic gene expression, and the response to various culture contexts (in vitro and xenografts). LNCaP cells had a more oxidative phenotype than PC3 and DU145 cells based upon respiration, lactate production, [ATP], metabolic gene expression, and sensitivity of these parameters to hypoxia. PC3 and DU145 cells possessed similar Complex II and mtDNA levels, but lower Complex III and IV activities, and were unresponsive to dinitrophenol or dichloroacetate, suggesting that their glycolytic phenotype is due to mitochondrial dysfunction rather than regulation. High passage under normoxia converted LNCaP from oxidative to glycolytic cells (based on respiration and lactate production), and altered metabolic gene expression. Though LNCaP-derived cells differed from the parental line in mitochondrial enzyme activities, none differed in mitochondrial content (assessed as cardiolipin levels). When LNCaP-derived cells were grown as xenografts in immunodeficient mice, there were elements of a hypoxic response (e.g., elevated VEGF mRNA) but line-specific changes in expression of select glycolytic, mitochondrial and fatty acid metabolic genes. Low oxygen in vitro did not influence the mRNA levels of SREBP axis, nor did it significantly alter triglyceride production in any of the cell lines suggesting that the pathway of de novo fatty acid synthesis is not directly upregulated by hypoxic conditions. Collectively, these studies demonstrate important differences in the metabolism of these prostate cancer models. Such metabolic differences would have important ramifications for therapeutic strategies involving metabolic targets.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19524545     DOI: 10.1016/j.bbabio.2009.06.003

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  35 in total

1.  Hyperpolarized [1-13C]-Pyruvate Magnetic Resonance Spectroscopic Imaging of Prostate Cancer In Vivo Predicts Efficacy of Targeting the Warburg Effect.

Authors:  Bradley T Scroggins; Masayuki Matsuo; Ayla O White; Keita Saito; Jeeva P Munasinghe; Carole Sourbier; Kazutoshi Yamamoto; Vivian Diaz; Yoichi Takakusagi; Kazuhiro Ichikawa; James B Mitchell; Murali C Krishna; Deborah E Citrin
Journal:  Clin Cancer Res       Date:  2018-03-29       Impact factor: 12.531

2.  Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate.

Authors:  Albert L Shroads; Taimour Langaee; Bonnie S Coats; Tracie L Kurtz; John R Bullock; David Weithorn; Yan Gong; David A Wagner; David A Ostrov; Julie A Johnson; Peter W Stacpoole
Journal:  J Clin Pharmacol       Date:  2011-06-03       Impact factor: 3.126

3.  Fructose-Bisphosphate Aldolase A Regulates Hypoxic Adaptation in Hepatocellular Carcinoma and Involved with Tumor Malignancy.

Authors:  Xin Li; Fengxing Jiang; Zhong Ge; Bin Chen; Jiang Yu; Mingjun Xin; Jiandong Wang; Lingxuan An; Jichao Wei; Liqun Wu
Journal:  Dig Dis Sci       Date:  2019-04-30       Impact factor: 3.199

Review 4.  Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Med       Date:  2011-05-20       Impact factor: 6.354

5.  Teriflunomide (leflunomide) promotes cytostatic, antioxidant, and apoptotic effects in transformed prostate epithelial cells: evidence supporting a role for teriflunomide in prostate cancer chemoprevention.

Authors:  Numsen Hail; Ping Chen; Lane R Bushman
Journal:  Neoplasia       Date:  2010-06       Impact factor: 5.715

6.  Targeting prostate cancer cell metabolism: impact of hexokinase and CPT-1 enzymes.

Authors:  Rouhallah Najjar Sadeghi; Fatemeh Karami-Tehrani; Siamak Salami
Journal:  Tumour Biol       Date:  2014-12-12

7.  Evolution of the oxygen sensitivity of cytochrome c oxidase subunit 4.

Authors:  K M Kocha; K Reilly; D S M Porplycia; J McDonald; T Snider; C D Moyes
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-12-17       Impact factor: 3.619

8.  Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism.

Authors:  Qiong Liu; Chris T Harvey; Hao Geng; Changhui Xue; Vivian Chen; Tomasz M Beer; David Z Qian
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

9.  3-Bromopyruvate induces rapid human prostate cancer cell death by affecting cell energy metabolism, GSH pool and the glyoxalase system.

Authors:  Daniela Valenti; Rosa A Vacca; Lidia de Bari
Journal:  J Bioenerg Biomembr       Date:  2015-11-03       Impact factor: 2.945

10.  Oxygenation as a driving factor in epithelial differentiation at the air-liquid interface.

Authors:  Sonya Kouthouridis; Julie Goepp; Carolina Martini; Elizabeth Matthes; John W Hanrahan; Christopher Moraes
Journal:  Integr Biol (Camb)       Date:  2021-03-17       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.